Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients
NCT ID: NCT06055907
Last Updated: 2023-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2023-05-15
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients
NCT05926518
The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients
NCT00351663
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
NCT03311984
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
NCT04558892
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
NCT04671160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NOR+ARG
Critically ill patients receiving norepinephrine and argipressin, with antithrombotic prophylaxis with 5000 IU of dalteparin.
Serum anti-Xa activity
4 hours after third dose of dalteparin, serum anti-Xa activity is measured
NOR
Critically ill patients receiving norepinephrine alone, with antithrombotic prophylaxis with 5000 IU of dalteparin.
Serum anti-Xa activity
4 hours after third dose of dalteparin, serum anti-Xa activity is measured
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum anti-Xa activity
4 hours after third dose of dalteparin, serum anti-Xa activity is measured
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Supported by continuous infusion of noradrenaline or noradrenaline and argipressin
* Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.
Exclusion Criteria
* Severe coagulopathy
* Acute or subacute bacterial endocarditis
* Pregnant women
* BMI (body mass index) \> 30kg/m2
* Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2
* Renal replacement therapy
* The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Gdansk
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Radosław Owczuk, MD., PhD., Prof.
Role: STUDY_DIRECTOR
Medical University of Gdansk
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care
Gdansk, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKN+JS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.